Preview | Issue Date | Title | Author(s) |
| 2007 | Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes | Schroth, W.; Antoniadou, L.; Fritz, P.; Schwab, M.; Muerdter, T.; Zanger, U.; Simon, W.; Eichelbaum, M.; Brauch, H. |
| 2001 | Distribution of microsomal epoxide hydrolase in humans: An immunohistochemical study in normal tissues, and benign and malignant tumours | Coller, J.; Fritz, P.; Zanger, U.; Siegle, I.; Eichelbaum, M.; Kroemer, H.; Murdter, T. |
| 2010 | Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study | Ribaudo, H.; Liu, H.; Schwab, M.; Schaeffeler, E.; Eichelbaum, M.; Motsinger-Reif, A.; Ritchie, M.; Zanger, U.; Acosta, E.; Morse, G.; Gulick, R.; Robbins, G.; Clifford, D.; Haas, D. |
| 2008 | Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALDI-TOF mass spectrometry: Reliable genotyping in different ethnic groups | Schaeffeler, E.; Zanger, U.; Eichelbaum, M.; Asante-Poku, S.; Shin, J.; Schwab, M. |
| 2004 | Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity | Coller, J.; Krebsfaenger, N.; Klein, K.; Wolbold, R.; Nussler, A.; Neuhaus, P.; Zanger, U.; Eichelbaum, M.; Murdter, T. |
| 2007 | Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4a: Evidence for direct regulation in the intestine | Tegude, H.; Schnabel, A.; Zanger, U.; Klein, K.; Eichelbaum, M.; Burk, O. |
| 2007 | Predictive value of known and novel alleles ofCYP2B6 for efavirenz plasma concentrations in HIV-infected individuals | Rotger, M.; Tegude, H.; Colombo, S.; Cavassini, M.; Furrer, H.; Decosterd, L.; Blievernicht, J.; Saussele, T.; Gunthard, H.; Schwab, M.; Eichelbaum, M.; Telenti, A.; Zanger, U. |
| 2008 | Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group | Schwab, M.; Zanger, U.; Marx, C.; Schaeffeler, E.; Klein, K.; Dippon, J.; Kerb, R.; Blievernicht, J.; Fischer, J.; Hofmann, U.; Bokemeyer, C.; Eichelbaum, M. |
| 2007 | Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole | Saussele, T.; Burk, O.; Blievernicht, J.; Nussler, A.; Nussler, N.; Hengstler, J.; Eichelbaum, M.; Schwab, M.; Zanger, U. |
| 2002 | The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver | Coller, J.; Krebsfaenger, N.; Klein, K.; Endrizzi, K.; Wolbold, R.; Lang, T.; Nussler, A.; Neuhaus, P.; Zanger, U.; Eichelbaum, M.; Murdter, T. |
| 2008 | Variability in human hepatic MRP4 expression: Influence of cholestasis and genotype | Gradhand, U.; Lang, T.; Schaeffeler, E.; Glaeser, H.; Tegude, H.; Klein, K.; Fritz, P.; Jedlitschky, G.; Kroemer, H.; Bachmakov, I.; Anwald, B.; Kerb, R.; Zanger, U.; Eichelbaum, M.; Schwab, M.; Fromm, M. |